| NFAT3 Protein | |
|---|---|
| Protein Name | Nuclear Factor of Activated T-cells 3 |
| Gene | [NFAT3](/genes/nfat3) |
| UniProt ID | [Q12968](https://www.uniprot.org/uniprot/Q12968) |
| PDB ID | 1p4h |
| Molecular Weight | 79 kDa |
| Subcellular Localization | Cytoplasm (inactive), Nucleus (active) |
| Protein Family | NFAT transcription factor family |
| Aliases | NFATc4, NFAT4 |
| Brain Expression | [Hippocampus](/brain-regions/hippocampus), cerebral [cortex](/brain-regions/cortex), basal ganglia |
NFAT3 (Nuclear Factor of Activated T-cells 3, also known as NFATc4 or NFAT4) is a calcium-dependent transcription factor belonging to the NFAT family. Unlike other NFAT isoforms that are widely expressed, NFAT3 exhibits more tissue-restricted expression with significant levels in the brain, cardiovascular system, and adipose tissue [1]. This page describes its structure, normal nervous system function, role in neurodegenerative disease, and potential as a therapeutic target.
NFAT3 is the smallest NFAT family member and contains several distinct domains:
The protein forms homodimers and heterodimers with other NFAT family members to bind DNA and regulate gene expression [2].
NFAT3 plays several important roles in normal brain function:
NFAT3, along with other NFAT isoforms, regulates genes involved in synaptic plasticity including:
During neural development, NFAT3 participates in:
As a calcium-dependent transcription factor, NFAT3 transduces calcium signals into gene expression changes:
NFAT3 also functions in glial cells:
NFAT3 (NFATc4) is implicated in several aspects of Alzheimer's disease pathology:
Amyloid-β Toxicity: Research demonstrates that amyloid-β peptide exposure leads to aberrant NFAT3 activation in neurons. This activation contributes to:
Tau Pathology: NFAT3 activation has been observed in tau-overexpressing neurons, where it may contribute to:
Therapeutic Implications: The calcineurin-NFAT pathway represents a potential therapeutic target. Studies using calcineurin inhibitors have shown neuroprotective effects in AD models, partially through modulation of NFAT3 activity [4].
In dopaminergic neurons, NFAT3 participates in:
Mitochondrial Dysfunction: NFAT3 regulates genes involved in mitochondrial biogenesis and quality control. Its dysregulation may exacerbate mitochondrial dysfunction in dopaminergic neurons.
Neuroinflammation: Microglial NFAT3 activation promotes expression of pro-inflammatory cytokines including:
α-Synuclein Pathology: Evidence suggests cross-talk between NFAT signaling and α-synuclein aggregation pathways [5].
Huntington's Disease: NFAT3 activation has been reported in striatal neurons expressing mutant huntingtin, where it contributes to transcriptional dysregulation.
Amyotrophic Lateral Sclerosis (ALS): Altered NFAT3 expression has been observed in spinal cord motor neurons in ALS models.
Multiple Sclerosis: In demyelinating conditions, NFAT3 regulates immune responses that affect oligodendrocyte survival.
NFAT3 interacts with several key proteins:
| Protein | Interaction Type | Functional Consequence |
|---|---|---|
| Calcineurin | Direct binding | Dephosphorylation, activation |
| GSK3β | Phosphorylation | Nuclear export |
| CK1 | Phosphorylation | Nuclear export |
| cAMP Response Element Binding Protein (CREB) | Co-activation | Synaptic gene expression |
| p53 | Cross-talk | Apoptosis regulation |
| NF-κB | Co-operative binding | Inflammatory gene expression |
| Class I HDACs | Repressor complex | Transcriptional repression |
The NFAT3 pathway offers several therapeutic opportunities:
Calcineurin Modulation: While immunosuppressants like cyclosporine A and FK506 inhibit calcineurin, their neuroprotective effects are complex due to pleiotropic actions.
NFAT-Selective Modulators: Developing compounds that selectively target NFAT3 without affecting immune function remains a challenge but would offer more specific therapy.
Kinase Inhibitors: GSK3β inhibitors (such as lithium) indirectly modulate NFAT3 activity and have been explored in AD therapy.
NFAT3 activation status in peripheral blood mononuclear cells (PBMCs) has been explored as a biomarker for:
Mouse models lacking NFAT3 show:
Transgenic models overexpressing NFAT3 in neurons exhibit:
NFAT3 is a calcium-dependent transcription factor with important roles in the nervous system. Its dysregulation contributes to the pathogenesis of multiple neurodegenerative diseases through effects on synaptic function, inflammation, and neuronal survival. While targeting the calcineurin-NFAT pathway shows therapeutic promise, selective modulation of NFAT3 remains challenging. Further research is needed to clarify its precise roles in neurodegeneration and develop targeted interventions.
NFAT transcription factors: from central nervous system development to neuronal function (Graef et al. [2001)](https://doi.org/10.1016/S0896-6273(01). 2001. ↩︎
Structure and function of the NFAT family and NFAT4 (Okamura et al. [2000)](https://doi.org/10.1016/S0092-8674(00). 2000. ↩︎
NFAT4 deficiency impairs neuronal development and function (Liu et al. 2005). 2005. ↩︎
Calcineurin-NFAT signaling in neurodegenerative diseases (Sullivan et al. 2020). 2020. ↩︎
NFAT activation in dopaminergic neuron death (Liu et al. 2018). 2018. ↩︎
NFAT3 in neuronal apoptosis and neurological disorders (Wang et al. 2022). 2022. ↩︎